Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)

Annals of Hematology

Volumn 91, Issue 7, 2012, Pages 1013-1022

  Rigacci, Luigi ^a   Puccini, Benedetta ^a   Cortelazzo, Sergio ^b   Gaidano, Gianluca ^c   Piccin, Andrea ^b   D'Arco, Alfonso ^d   Freilone, Roberto ^e   Storti, Sergio ^f   Orciuolo, Enrico ^g   Zinzani, Pier Luigi ^h   Zaja, Francesco ⁱ   Bongarzoni, Velia ^j   Balzarotti, Monica ^k   Rota Scalabrini, Delia ^l   Patti, Caterina ^m   Gobbi, Marco ⁿ   Carpaneto, Andrea ^o   Liberati, Anna Marina ^p   Bosi, Alberto ^a   Iannitto, Emilio ^q  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Ospedale Regionale San Maurizio   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UO Ematologia   (Italy)

^e SC Medicina Trasfusionale Ed Ematologia   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ Clinica Ematologica   (Italy)

^j SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^k HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^l CANDIOLO CANCER INSTITUTE   (Italy)

^m UO Ematologia   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o UO Ematologia   (Italy)

^p S MARIA HOSPITAL   (Italy)

^q UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

Antineoplastic agents; Bendamustine; Relapsed lymphoma; Rituximab

Indexed keywords

BENDAMUSTINE; RITUXIMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPITHELIUM TUMOR; ERYTHRODERMA; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HERPES ZOSTER; HUMAN; HYPERNATREMIA; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; METABOLIC DISORDER; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NON FOLLICULAR LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOUNDATIONS; HUMANS; ITALY; LYMPHOMA, NON-HODGKIN; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84862774641     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1422-5     Document Type: Article

References (27)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics 2008 CA Cancer J Clin. 58 71 96 18287387 10.3322/CA.2007.0010
2. P Boyle J Ferlay 2005 Cancer incidence and mortality in Europe, 2004 Ann. Oncol. 16 481 488 15718248 10.1093/annonc/mdi098 1:STN:280: DC%2BD2M%2FptVGrsA%3D%3D
3. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelik J Vardiman TA Lister CD Bloomfield 2000 The Word Health Organization Classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997 Mod Pathol. 13 2 193 207 10697278 10.1038/modpathol.3880035 1:STN:280:DC%2BD3c7mtVemsw%3D%3D
4. JM Vose PJ Bierman JR Anderson A Kessinger J Pierson J Nelson B Prappier K Schmit-Pokorny DD Weisenburger JO Armitage 1992 Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up Blood 80 8 2142 2148 1356515 1:STN:280:DyaK3s%2FgsVOrsA%3D%3D
5. RL Elstrom P Martin K Ostrow J Barrientos A Chadburn R Furman J Ruan T Shore M Schuster L Cerchietti A Melnick M Coleman JP Leonard 2010 Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies Clin Lymphoma Myeloma Leuk 10 3 192 196 20511164 10.3816/CLML.2010.n.030 1:CAS:528:DC%2BC3cXotlCrtLs%3D
6. JA Barman Balfour KL Goa 2001 Bendamustine Drugs 61 5 631 638 10.2165/00003495-200161050-00009
7. LM Leoni B Bailey J Reifert HH Bendall RW Zeller J Corbeil G Elliot CC Niemeyer 2008 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkilating agents Clin Cancer Res 14 309 317 18172283 10.1158/1078-0432.CCR-07-1061 1:CAS:528:DC%2BD1cXoslKk
8. D Strumberg A Harsdtrick K Doll B Hoffmann S Seeber 1996 Bendamustine hydrochloride activity against doxorubicin-resistent human breast carcinoma cell lines Anticancer Drugs 7 415 421 8826610 10.1097/00001813-199606000-00007 1:CAS:528:DyaK28XkslWru7g%3D
9. LM Leoni B Bailey J Reifert 2003 SDX-105 (bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action Blood; 102 640a
10. M Montillo F Ricci A Tedeschi E Vismara E Morra 2010 Bendamustine: new perspective for an old drug in lymphoprolipherative disorders Expert. Rev. Hematol. 3 2 131 148 21083456 10.1586/ehm.10.7 1:CAS:528:DC%2BC3cXktlCltbY%3D
11. JW Friedberg P Cohen L Chen KS Robinson A Forero-Torres AS La Casce LE Fayad A Bessudo ES Camacho ME Williams RH van der Jagt JW Oliver BD Cheson 2008 Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study J. Clin. Oncol. 26 204 210 18182663 10.1200/JCO.2007.12.5070 1:CAS:528:DC%2BD1cXitVWit70%3D
12. K Bremer 2002 High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphoma J Cancer Res Clin Oncol 128 603 609 12458340 10.1007/s00432-002-0378-6 1:CAS:528:DC%2BD3sXptVyiuw%3D%3D
13. C Ujjani B Cheson 2011 Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial Future Oncol 7 1 9 14 21174533 10.2217/fon.10.169 1:CAS:528:DC%2BC3cXhs1Sju7rE
14. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors TA Lister J Vose A Grillo-Lopez A Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino NL Harris JO Armitage W Carter R Hoppe GP Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol. 17 1244 1253 10561185 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D
15. SPSS Inc. (1998) SPSS for Windows, version 12.0. Chicago: SPSS.
16. A Heider N Niederle 2001 Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma Anticancer Drugs 12 725 729 11593053 10.1097/00001813-200110000-00003 1:CAS:528:DC%2BD3MXosVKltLk%3D
17. R Kath K Blumenstengel HJ Fricke K Hoffken 2001 Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia J. Cancer Research Clin Oncol. 127 48 54 10.1007/s004320000180 1:CAS:528:DC%2BD3MXitVOqsg%3D%3D
18. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP.(2011) The combination of bendamustine,bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, Jan 14 Epub
19. MJ Rummel SE Al-Batran SZ Kim M Welsalu R Hecker D Kofahl-Krause KM Josten H Durk A Rost M Neise U von Grunhagen KU Chow ML Hansmann D Holzer PS Mitrou 2005 Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low grade non-Hodgkin's lymphoma J. Clin. Oncol. 23 15 3383 3389 15908650 10.1200/JCO.2005.08.100 1:CAS:528:DC%2BD2MXlsVyiu7k%3D
20. BD Cheson JW Friedberg BS Kahl RH Van der Jagt L Tremmel 2010 Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma Clin Lymphoma Myeloma Leuk 10 6 452 457 21189660 10.3816/CLML.2010.n.079 1:CAS:528: DC%2BC3MXjslenuw%3D%3D
21. K Ohmachi K Ando M Ogura T Uchida K Itoh N Kubota K Ishizawa J Yamamoto T Watanabe N Uike I Choi Y Terui K Usuki H Nagai N Uoshima K Tobinai 2010 Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma Cancer Sci 101 9 2059 2064 20626754 10.1111/j.1349-7006.2010.01635.x 1:CAS:528:DC%2BC3cXhtFylu7bI
22. R Weide A Pandorf J Heymanns, et al. 2004 Bendamustine/mitoxantrone/ rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20 positive indolent malignancies Final results of a pilot study. Leukemia and Lymphoma 45 2445 2449 10.1080/10428190400004521 1:CAS:528:DC%2BD2cXhtVKru7rM
23. T Lissitchkov G Arnaudov D Peytchev KH Merkle 2006 Phase I/II study to evaluate dose limiting toxicity, massimum tolerated doses, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukemia (binet stage) requiring therapy J Cancer Res Clin Oncol 132 99 104 16292542 10.1007/s00432-005-0050-z 1:CAS:528:DC%2BD2MXht1Oqsb7L
24. P Schoffski G Seeland H Engel V Grunwald H Paul K Merkle R Kowalski A Ganser 2000 Weekly administration of bendamustine a phase I study in patients with advanced progressive solid tumors Ann Oncol 11 729 735 10942063 10.1023/A:1008309911008 1:STN:280:DC%2BD3MzgsVejtw%3D%3D
25. M Rasschaert D Schrijvers J Van den Brande J Dyck J Bosmans K Merkle JB Vermorken 2007 A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumors Br J Cancer 96 1692 1698 17486132 10.1038/sj.bjc.6603776 1:CAS:528:DC%2BD2sXlvVShsbg%3D
26. BD Cheson CM Wendtner A Pieper M Dreyling J Friedberg D Hoelzer P Moreau J Gribben S Knop M Montillo M Rummel 2010 Optimal use of bendamustine in chronic lymphocytic leukemia, non Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel Clin Lymphoma Myeloma Leuk 10 21 27 20223726 10.3816/CLML.2010.n.002
27. st ASH Meeting